triumph trial retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the registrational clinical trials I personally know plenty of
Description
exendin(939) was from Thermoscientific (local distributor: Th
It starts with an initial dose of 0.25 mg, increased every 4 weeks until the maximum maintenance dose of 2.4 mg is reached
Moderate risk, defined by one clinical threshold or contextual red flag, should prompt structured interventions such as group-based CBT or tele-coaching, alongside monthly reviews
[DOI] [PMC free article] [PubMed] [Google Scholar] 6.Zhou X.D., Chen Q.F., Yang W., Zuluaga M., Targher G., Byrne C.D., Valenti L., Luo F., Katsouras C.S., Thaher O., et al
N Engl J Med 2015;373:224757.ArticlePubMed 67
36 A post-hoc analysis of the FIGHT trial also demonstrated a trend towards an increase in arrhythmic events in patients on liraglutide (21 versus 39
